Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676406 | 1.00 | HTR2A (0.55) | HTR2ASIGMAR1ALDH1A1TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL2803727 | 0.98 | HTR2A (0.53) | HTR2ASIGMAR1ALDH1A1TP53CYP1A2 | |
| Butane SCHEMBL8571253 | 0.91 | SIGMAR1 (0.56) | HTR2ASIGMAR1ALDH1A1TP53CYP1A2 | |
| SCHEMBL155826 | 0.89 | SIGMAR1 (0.53) | HTR2ASIGMAR1TP53CYP1A2CYP3A4 | |
| SCHEMBL30841243 | 0.89 | SIGMAR1 (0.53) | HTR2ASIGMAR1TP53CYP1A2CYP3A4 | |
| SCHEMBL1222048 | 0.89 | HTR2A (0.61) | HTR2ASIGMAR1ALDH1A1TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL238199 | 0.87 | SIGMAR1 (0.54) | HTR2ASIGMAR1TP53CYP1A2CYP3A4 | |
| SCHEMBL7382981 | 0.87 | SIGMAR1 (0.54) | HTR2ASIGMAR1TP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL31137663 | 0.87 | HTR2A (0.59) | HTR2ASIGMAR1ALDH1A1TP53CYP1A2 | |
| SCHEMBL29860963 | 0.85 | SIGMAR1 (0.58) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4320125-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | claimed |
| US-20120316143-A1 | Ophthalmic composition | SOLL DAVID B (US) | 2012-12-13 | — | — | US | claimed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024229317-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4320125-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117396477-A | Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-01-26 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| EP-0722941-A2 | Compounds having effects on serotonin-related systems | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0662481-A1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO. INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994019367-A1 | SPIRO PIPERIDINES AND HOMOLOGS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| US-5324733-A | Selective ligands at sigma recognition sites | MERCK SHARPE & DOHME LTD. | 1994-06-28 | — | — | US | disclosed |
| EP-0593511-A1 | PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT | H. LUNDBECK A/S (DK) | 1994-04-27 | — | — | EP | disclosed |
| US-5219860-A | Neuroleptic agents | MERCK SHARP & DOHME LIMITED (GB) | 1993-06-15 | — | — | US | disclosed |
| WO-1992022554-A1 | PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT | H. LUNDBECK A/S (DK) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518805-A1 | Piperidine derivatives | H. LUNDBECK A/S (DK) | 1992-12-16 | — | — | EP | disclosed |
| EP-0445974-A2 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | HTR2A 1754/4885SIGMAR1 4301/4885ALDH1A1 3594/4885 |
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | HTR2A 3498/4885SIGMAR1 2357/4885ALDH1A1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.